The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival-Reference-Cited by-同舟云学术

The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival

Published:2020-03-09 Issue:4 Volume:190 Page:545-554
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Bishton Mark J.¹^ORCID,Rule Simon²,Wilson William³,Turner Deborah⁴,Patmore Russell⁵,Clifton‐Hadley Laura³,McMillan Andrew⁶,Lush Richard⁷,Haynes Andrew⁸

Affiliation:

1. Clinical Haematology Nottingham City Hospital NottinghamUK

2. Department of Haematology University of Plymouth Medical School Plymouth UK

3. CRUK and UCL Cancer Trials Centre University College London London UK

4. Department of Haematology Torbay and South Devon NHS Trust TorquayUK

5. Queen's Centre for Oncology and Haematology Hull and East Yorkshire Hospitals CottinghamUK

6. Centre for Clinical Haematology Nottingham University Hospitals Nottingham UK

7. Department of Haematology Gloucestershire Hospitals NHS Foundation Trust Cheltenham UK

8. Sherwood Forest Hospitals NHS Foundation Trust Sutton‐In‐Ashfield UK

Funder

Schering-Plough

University College London